1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,955 | 0,980 | 16:49 | |
| 0,955 | 0,980 | 16:45 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:38 | NanoViricides: Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo | 319 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / September 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces... ► Artikel lesen | |
| 31.08. | While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles | 668 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / August 31, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development... ► Artikel lesen | |
| 18.08. | NanoViricides: The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon | 1.135 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / August 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that... ► Artikel lesen | |
| 10.08. | NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak | 10.831 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / August 10, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that... ► Artikel lesen | |
| 30.07. | NANOVIRICIDES, INC. - 8-K, Current Report | 9 | SEC Filings | ||
| NANOVIRICIDES Aktie jetzt für 0€ handeln | |||||
| 28.07. | NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial | 9.141 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 28, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that... ► Artikel lesen | |
| 24.07. | NanoViricides announces $3.8M registered direct offering; shares down | 5 | Seeking Alpha | ||
| 24.07. | NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering | 1.455 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 24, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("NanoViricides" or the "Company"), a clinical stage, leading global pioneer in the development of broad-spectrum... ► Artikel lesen | |
| 22.07. | As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola | 8.849 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 22, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that... ► Artikel lesen | |
| 17.07. | NANOVIRICIDES, INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 13.07. | As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo | 701 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 13, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that... ► Artikel lesen | |
| 08.07. | Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily | 791 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, reports that a... ► Artikel lesen | |
| 06.07. | Noble Capital startet Coverage für NanoViricides mit "Outperform" | 1 | Investing.com Deutsch | ||
| 06.07. | Noble Capital initiates NanoViricides stock with Outperform rating | 3 | Investing.com | ||
| 06.07. | As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo | 636 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 6, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, updates that it... ► Artikel lesen | |
| 29.06. | NanoViricides: US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher | 863 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / June 29, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of... ► Artikel lesen | |
| 22.06. | NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo | 1.076 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / June 22, 2026 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company") today announced that it has shipped the NV-387 Oral Gummies Drug Product for a Phase II Clinical... ► Artikel lesen | |
| 15.06. | As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo | 1.165 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / June 15, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, NanoViricides... ► Artikel lesen | |
| 08.06. | As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies | 884 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / June 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, NanoViricides... ► Artikel lesen | |
| 26.05. | In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides | 934 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / May 26, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, compares potential... ► Artikel lesen |
1 2 3 Weiter >>
53 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FORMYCON | 20,500 | -0,24 % | Formycon Aktie: Ist der Umsatzsprung erst der Anfang? | ||
| ONTO INNOVATION | 230,40 | +1,23 % | Morgan Stanley cuts Onto Innovation stock price target on mix dynamics | ||
| RIBER | 8,740 | +2,82 % | RIBER: FIRST-HALF 2026 BUSINESS ACTIVITY Business growth, resilient order book and continued rollout of ROSIE | FIRST-HALF 2026 BUSINESS ACTIVITYBusiness growth, resilient order book and continued rollout of ROSIE Bezons, July 22, 2026 - 8:00 am - RIBER, the global leader in molecular beam epitaxy (MBE) equipment... ► Artikel lesen | |
| GAUZY | 0,371 | -5,72 % | Gauzy Ltd. Announces Receipt of Nasdaq Notice Regarding Delayed Filing of Annual Report on Form 20-F | TEL AVIV, Israel, May 26, 2026 (GLOBE NEWSWIRE) -- Gauzy Ltd. (NASDAQ: GAUZ) ("Gauzy" or the "Company"), a global leader in vision and light control technologies, today announced that on May 19, 2026... ► Artikel lesen | |
| SMOLTEK NANOTECH | 0,119 | +1,71 % | SMOLTEK NANOTECH HOLDING AB: Smoltek appoints Gabriel Altby as Chief Operating Officer | ||
| SOLESENCE | 0,830 | 0,00 % | Solésence, Inc.: Solésence Reports Second Quarter 2026 Financial Results | Quarterly Report Filed on Form 10-Q Company to Host Conference Call at 5:00 p.m. ET Today ROMEOVILLE, Ill., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically... ► Artikel lesen | |
| GOMSPACE | 0,990 | +1,28 % | GomSpace A/S: D-Orbit Selects GomSpace Power Systems for Upcoming Space Logistics Missions | STOCKHOLM, Sept. 1, 2026 /PRNewswire/ -- GomSpace, leading provider of pre-engineered products for space missions, announced that D-Orbit, a global leader in space logistics and orbital transportation... ► Artikel lesen | |
| KOPIN | 3,730 | +1,19 % | Kopin wins $2.4M OLED microdisplay order | ||
| NVE | 85,00 | -1,16 % | Dividendenbekanntmachungen (03.08.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AMERISERV FINANCIAL INC US03074A1025 0,03 USD 0,026 EUR BF SPA IT0005187460 - 0,038 EUR CITIZENS & NORTHERN CORPORATION US1729221069 0... ► Artikel lesen | |
| VEECO INSTRUMENTS | 39,180 | +1,63 % | Veeco Instruments Inc.: Veeco Reports Second Quarter 2026 Financial Results | Second Quarter 2026 Highlights: Revenue of $193.5 million, compared with $166.1 million in the same period last yearGAAP net income of $11.9 million, or $0.18 per diluted share, compared with $11.7... ► Artikel lesen | |
| ACACIA RESEARCH | 3,820 | 0,00 % | ACACIA RESEARCH CORP - 10-Q, Quarterly Report | ||
| ADVANCE ZINCTEK | 0,374 | 0,00 % | Advance Zinctek Ltd Profit Advances In Full Year | ||
| LAMPETIA | 0,161 | -9,04 % | EQS-Adhoc: Lampetia AG: Einigung über die Beendigung von Rechtsstreitigkeiten | EQS-Ad-hoc: Lampetia AG / Schlagwort(e): Sonstiges
Lampetia AG: Einigung über die Beendigung von Rechtsstreitigkeiten
16.07.2026 / 22:00 CET/CEST
Veröffentlichung einer Insiderinformation... ► Artikel lesen | |
| DOTZ NANO | 0,010 | 0,00 % | Thursday's HotCopper trends: Vanadium Resources, MaxiPARTS, Dotz Nano and other daily topics | ||
| ANTEOTECH | 0,006 | 0,00 % | XFRA NEW INSTRUMENTS AVAILABLE ON 08.09.2026 | The following instruments on XETRA do have their first trading 08.09.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 08.09.2026
Aktien
1 US3611181021 Furukawa Electric Co.... ► Artikel lesen |
NANOVIRICIDES INC gehört der Branche Nanotechnologie an. Mit einer aktuellen Kursveränderung von +0,010 (+1,04 %) liegt der Kurs bei 0,970 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOVIRICIDES INC finden Sie auf Wallstreet Online.